Table 1.
Diagnostic accuracy of MRI modalities.
| Technique | Participants (n) | Sensitivity (%) | Specificity (%) |
|---|---|---|---|
| Abnormal putaminal T2 hypointensity | MSA-P (24) vs PD (27) | 87.5 | 88.89 |
| Proton density putaminal hyperintensity | MSA-P (24) vs PD (27) | 83.3 | 100 |
| T1 MRI: midbrain superior profile | PSP (25) vs PD (27) | 68 | 88.8 |
| T1 MRI: midbrain atrophy | PSP (25) vs PD (27) | 68 | 77.7 |
| T2 MRI: tegmental hyperintensity | PSP (25) vs PD (27) | 28 | 100 |
| Putaminal T2 hypointensity T2 hyperintensity combined | MSA (28) vs PD (32) PSP (30) CBD (26) | 32 32 32 | 100 93 85 |
| Overall MRI abnormalities | PD (32) vs MSA (28) PSP (30) CBD (26) | 71 70 92 | 91 91 91 |
| T1 MRI: voxel-based morphometry of cerebral peduncles and midbrain | PSP (12) versus PD (12) | 83 | 79 |
| Diffusion-weighted MRI Putaminal rADC | MSA-P (10) vs PD (11) | 100 | 100 |
| Putaminal hyperintense rim | MSA-P (10) vs PD (11) | 80 | 91 |
| Putaminal atrophy | MSA-P (10) vs PD (11) | 60 | 100 |
CBD = corticobasalganglionic degeneration; MRI = magnetic resonance imaging; MSA-P = multiple system atrophy parkinsonian type; PD = Parkinson’s disease; PSP = progressive supranuclear palsy; rADC = regional apparent diffusion coefficient.